Corcept Therapeutics (CORT) Tops Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.85 +0.18%
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.09 better than the analyst estimate of $0.23. Revenue for the quarter came in at $163.8 million versus the consensus estimate of $155.22 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Enanta Pharma loses appeal in Pfizer Paxlovid patent case
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
